Eli Lilly Achieves 45% Risk Reduction in Phase 3 CLL Trial, Hits $1T Valuation
LLY•Lilly's Phase 3 BRUIN CLL-322 trial showed that adding pirtobrutinib to venetoclax and rituximab cut progression or death risk by 45% and will support FDA label expansion submission. The company's stock has soared 400% to a $1 trillion market cap at 40x earnings, driven by GLP-1 drugs Mounjaro and Zepbound.
1. Phase 3 BRUIN CLL-322 Trial Success
The BRUIN CLL-322 trial met its primary endpoint by demonstrating that adding pirtobrutinib to venetoclax and rituximab reduced the risk of disease progression or death by 45%. Benefits were consistent across high-risk chronic lymphocytic leukemia patient groups, positioning Lilly to submit data for regulatory label expansion.
2. Record Stock Rally and Valuation
Lilly's shares have climbed over 400% in the past five years, propelling the company to a $1 trillion market cap and a trading multiple near 40x earnings. This rally has been driven by blockbuster GLP-1 therapies Mounjaro and Zepbound, alongside strategic acquisitions in RNA therapies and infectious diseases to fuel future growth.
